Cipla's Advair Generic Debut Is In Sight
More Platform Deals On Radar Post Ethris, Stem Cell Therapy Well Received
Executive Summary
Cipla believes it is “pretty close” to approval for its Advair generic in the US, while another product, generic Abraxane, stands delayed currently. Following the deal with Ethris, which is progressing inhaled mRNA-based therapies, the company signals interest in platforms such as CAR-T as well.